Pular para o conteúdo

FDA Requires a Warning About Rare Vision Loss (NAION) on All GLP-1 Drugs, From Ozempic and Wegovy to Mounjaro and Zepbound

10 de novembro de 2026 · 7 min

Notas do episódio

On November 9, 2026, the US Food and Drug Administration said it is requiring the makers of all GLP-1 receptor agonist medicines, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound and Foundayo, to add information to the Warnings and Precautions section of their labels about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause sudden, painless vision loss in one eye, including permanent vision loss. In an FDA analysis of 126 randomized trials with 134,253 patients, there were 10 probable NAION cases among people on GLP-1 drugs and 5 among people on placebo, or 6.4 versus 3.8 cases per 100,000 person-years. An FDA Sentinel study in adults with type 2 diabetes found a higher risk with GLP-1 drugs than with DPP-4 inhibitors but no statistically significant difference compared with SGLT2 inhibitors, and FDA's review of animal data did not identify a mechanism. FDA describes the risk as potential. We also cover the 2024 JAMA Ophthalmology study that prompted FDA's review, the European Medicines Agency's June 2025 conclusion that NAION is a very rare side effect of semaglutide, and statements from Novo Nordisk and Eli Lilly.

Sources

  • FDA Drug Safety Communication (Nov 9, 2026), labeling changes for GLP-1 receptor agonists due to potential increased risk of NAION: fda.gov
  • Reuters (Nov 9, 2026), US FDA orders new eye risk warnings for Ozempic, Zepbound: investing.com
  • Bloomberg (Nov 9, 2026), FDA adds warning label to obesity drugs for eye condition, with Novo Nordisk and Lilly statements: ndtvprofit.com
  • Healio (Nov 9, 2026), FDA to require NAION risk warning for GLP-1 therapies: healio.com
  • European Medicines Agency (June 6, 2025), PRAC concludes NAION is a very rare side effect of semaglutide medicines: ema.europa.eu
  • JAMA Ophthalmology (2024), Hathaway et al., risk of NAION in patients prescribed semaglutide (PubMed abstract): pubmed.ncbi.nlm.nih.gov

Cover: original code-generated illustration (no photo).

This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.

Visit glp1newspaper.com for today's stories and free email alerts.

Todos os episódios de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Configurações

Exibição

Idioma

Define quais estações você vê primeiro na página inicial.

Histórico

As rádios e episódios ouvidos recentemente e suas últimas buscas ficam só neste navegador.

Avisos

Um aviso rápido quando um podcast que você segue tem um episódio novo. Desative podcasts individuais pelo sino na página deles.

Conta

Salve favoritos – no app e no site.

Atalhos de teclado

/
Abrir busca
Espaço
Reproduzir ou pausar
← →
No player: voltar 15 s, avançar 30 s (episódios) · na fileira: próximo bloco
↑ ↓
Na fileira: alvo dentro do bloco
Home / End
Na fileira: primeiro ou último bloco
Esc
Fechar janela ou menu
?
Esta visão geral
Tocando agora

Ir para a estação

A seguir

    Adicione episódios com “A seguir” – eles tocam depois do episódio atual.